Management of hypertension at the community level in Sub-Saharan Africa (SSA): Towards a rational use of available resources

Journal of Human Hypertension

Volumn 25, Issue 1, 2011, Pages 47-56

  Twagirumukiza, M ^a,b   Van Bortel, L M ^b  

^a UNIVERSITY OF RWANDA   (Rwanda)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

African continental ancestry groups; cost of illness; prevalence; sub Saharan Africa

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; HYDROCHLOROTHIAZIDE; PRAZOSIN; RAUWOLFIA EXTRACT; RESERPINE; THIAZIDE DIURETIC AGENT;

AFRICA; ALGORITHM; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RISK; COMMUNITY CARE; DEPRESSION; DRUG DOSE INCREASE; HEALTH CARE MANAGEMENT; HEALTH CARE UTILIZATION; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; LOW DRUG DOSE; LOWEST INCOME GROUP; NOSE CONGESTION; PRACTICE GUIDELINE; RISK ASSESSMENT;

ADOLESCENT; ADULT; AFRICA SOUTH OF THE SAHARA; AGED; AGED, 80 AND OVER; ALGORITHMS; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; COMMUNITY HEALTH SERVICES; GREAT BRITAIN; HEALTH CARE COSTS; HEALTH CARE RATIONING; HEART FAILURE; HUMANS; HYPERTENSION; MIDDLE AGED; RISK FACTORS; UNITED STATES; YOUNG ADULT;

EID: 78650178612     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2010.32     Document Type: Article

References (66)

1. World Health OrganizationMackay J, Mensah G. The Atlas of Heart Disease and Stroke, 2004. Geneva: WHO, 2004.
2. Mendis S. Challenges for the management of hypertension in low-resource settings. Ethn Dis 2003; 13(2 Suppl 2): S67-S70.
3. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: Systematic analysis of population health data. Lancet 2006; 367(9524): 1747-1757. (Pubitemid 43767064)
4. Gaziano TA. Reducing the growing burden of cardiovascular disease in the developing world. Health Aff 2007; 26(1): 13-24.
5. Nadar SK, Tayebjee MH, Messerli F, Lip GY. Target organ damage in hypertension: Pathophysiology and implications for drug therapy. Curr Pharm Des 2006; 12(13): 1581-1592.
6. M0Buyamba-Kabangu JR, Biswika RT, Thijs L, Tshimanga GM, Ngalula FM, Disashi T et al. In-hospital mortality among black patients admitted for hypertension- related disorders in Mbuji Mayi, Congo. Am J Hypertens 2009; 22(6): 643-648.
7. Lenfant C. Can we prevent cardiovascular diseases in low- and middle-income countries? Bull World Health Organ 2001; 79(10): 980-982.
8. Jeffries D. Risk in cardiovascular disease. Having so many different guidelines about reducing risk is confusing. BMJ 2000; 321(7254): 175.
9. Whitworth JA. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21(11): 1983-1992. (Pubitemid 38296854)
10. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G et al. 2007 Guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25(6): 1105-1187. (Pubitemid 46924065)
11. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report. JAMA 2003; 289(19): 2560-2572. (Pubitemid 37430158)
12. Lemogoum D, Seedat YK, Mabadeje AF, Mendis S, Bovet P, Onwubere B et al. Recommendations for prevention, diagnosis and management of hypertension and cardiovascular risk factors in sub-Saharan Africa. J Hypertens 2003; 21(11): 1993-2000. (Pubitemid 38296855)
13. Douglas JG, Bakris GL, Epstein M, Ferdinand KC, Ferrario C, Flack JM et al. Management of high blood pressure in African Americans: Consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med 2003; 163(5): 525-541. (Pubitemid 36314340)
14. World Health Organization (WHO). CVD-Risk Management Package for Low and Medium Resource Settings. Geneva: WHO, 2002.
15. Ajayi AA. Recommendations for prevention, diagnosis and management of hypertension and cardiovascular risk factors in sub-Saharan Africa. J Hypertens 2004; 22(5): 1047.
16. Gaziano TA, Steyn K, Cohen DJ, Weinstein MC, Opie LH. Cost-effectiveness analysis of hypertension guidelines in South Africa: Absolute risk versus blood pressure level. Circulation 2005; 112(23): 3569-3576. (Pubitemid 43739534)
17. Elliott WJ. The costs of treating hypertension: What are the long-term realities of cost containment and pharmacoeconomics? Postgrad Med 1996; 99(4): 241-242.
18. Amira CO, Okubadejo NU. Antihypertensive pharmacotherapy in a developing economy: Pattern, acquisition costs and conformity to international guidelines in a tertiary-care setting. J Hum Hypertens 2006; 20(11): 894-897. (Pubitemid 44614073)
19. Cooper RS, Rotimi CN, Kaufman JS, Muna WF, Mensah GA. Hypertension treatment and control in sub- Saharan Africa: The epidemiological basis for policy. BMJ 1998; 316(7131): 614-617. (Pubitemid 28121000)
20. Gaziano TA. Cardiovascular disease in the developing world and its cost-effective management. Circulation 2005; 112(23): 3547-3553. (Pubitemid 43739531)
21. Cooper RS, Rotimi C. Hypertension in populations of West African origin: Is there a genetic predisposition? J Hypertens 1994; 12(3): 215-227. (Pubitemid 24090024)
22. Cappuccio FP, Micah FB, Emmett L, Kerry SM, Antwi S, Martin-Peprah R et al. Prevalence, detection, management, and control of hypertension in Ashanti, West Africa. Hypertension 2004; 43(5): 1017-1022. (Pubitemid 38579907)
23. Ndiaye P, Soors W, Criel B. Editorial: A view from beneath: Community health insurance in Africa. Trop Med Int Health 2007; 12(2): 157-161.
24. Mensah GA, Barkey NL, Cooper RS. Spectrum of hypertensive target organ damage in Africa: A review of published studies. J Hum Hypertens 1994; 8(11): 799-808. (Pubitemid 24359367)
25. Marijon E, Trinquart L, Jani D, Jourdier H, Garbarz E, Mocumbi AO et al. Coronary heart disease and associated risk factors in sub-Saharan Africans. J Hum Hypertens 2007; 21(5): 411-414. (Pubitemid 46637948)
26. Essop MR, Nkomo VT. Rheumatic and nonrheumatic valvular heart disease: Epidemiology, management, and prevention in Africa. Circulation 2005; 112(23): 3584-3591. (Pubitemid 43739536)
27. Twagirumukiza M, Nkeramihigo E, Seminega B, Gasakure E, Boccara F, Barbaro G. Prevalence of dilated cardiomyopathy in HIV-infected African patients not receiving HAART: A multicenter, observational, prospective, cohort study in Rwanda. Curr HIV Res 2007; 5(1): 129-137. (Pubitemid 46062366)
28. Lutale JJ, Thordarson H, Gulam-Abbas Z, Vetvik K, Gerdts E. Prevalence and covariates of electrocardiographic left ventricular hypertrophy in diabetic patients in Tanzania. Cardiovasc J Afr 2008; 19(1): 8-14. (Pubitemid 351579083)
29. Seedat YK. Hypertension in developing nations in sub- Saharan Africa. J Hum Hypertens 2000; 14(10-11): 739-747.
30. Ntusi NB, Mayosi BM. Epidemiology of heart failure in sub-Saharan Africa. Expert Rev Cardiovasc Ther 2009; 7(2): 169-180.
31. Strong K, Mathers C, Bonita R. Preventing stroke: Saving lives around the world. Lancet Neurol 2007; 6(2): 182-187. (Pubitemid 46097543)
32. Walker RW, McLarty DG, Kitange HM, Whiting D, Masuki G, Mtasiwa DM et al. Stroke mortality in urban and rural Tanzania. Adult morbidity and mortality project. Lancet 2000; 355(9216): 1684-1687. (Pubitemid 30248481)
33. Matekole M, Affram K, Lee SJ, Howie AJ, Michael J, Adu D. Hypertension and end-stage renal failure in tropical Africa. J Hum Hypertens 1993; 7(5): 443-446. (Pubitemid 23310605)
34. Milne FJ, James SH, Veriava Y. Malignant hypertension and its renal complications in black South Africans. S Afr Med J 1989; 76(4): 164-167. (Pubitemid 19230696)
35. Veriava Y, du Toit E, Lawley CG, Milne FJ, Reinach SG. Hypertension as a cause of end-stage renal failure in South Africa. J Hum Hypertens 1990; 4(4): 379-383. (Pubitemid 20260453)
36. Walker RW, McLarty DG. Hypertension and stroke in developing countries. Lancet 1995; 346(8977): 778.
37. Matenga JA, Allain TJ, Wilson AO, Adamchak DJ, Senzanje B, Mushangi E et al. Hypertension management in Zimbabwe: Awareness, treatment and blood pressure control. A community-based study. S Afr Med J 1997; 87(10): 1371-1373. (Pubitemid 28010603)
38. Mufunda J, Chatora R, Ndambakuwa Y, Nyarango P. Emerging non-communicable disease epidemic in Africa: Preventive measures from the WHO regional office for Africa. Ethn Dis 16(2): 521-526.
39. Reddy KS, Yusuf S. Emerging epidemic of cardiovascular disease in developing countries. Circulation 1998; 97(6): 596-601. (Pubitemid 28090690)
40. Maire B, Lioret S, Gartner A, Delpeuch F. Nutritional transition and non-communicable diet-related chronic diseases in developing countries. Revue Santé 2002; 12(1): 45-55. (Pubitemid 34309410)
41. Abegunde DO, Mathers CD, Adam T, Ortegon M, Strong K. The burden and costs of chronic diseases in low-income and middle-income countries. Lancet 2007; 370(9603): 1929-1938. (Pubitemid 350192633)
42. Bovet P, Ross AG, Gervasoni JP, Mkamba M, Mtasiwa DM, Lengeler C et al. Distribution of blood pressure, body mass index and smoking habits in the urban population of Dar es Salaam, Tanzania, and associations with socioeconomic status. Int J Epidemiol 2002; 31(1): 240-247. (Pubitemid 34284933)
43. Cappuccio FP, Plange-Rhule J, Phillips RO, Eastwood JB. Prevention of hypertension and stroke in Africa. Lancet 2000; 356(9230): 677-678.
44. Opie LH, Seedat YK. Hypertension in sub-Saharan African populations. Circulation 2005; 112(23): 3562-3568. (Pubitemid 43739533)
45. Appel LJ, Champagne CM, Harsha DW, Cooper LS, Obarzanek E, Elmer PJ et al. Effects of comprehensive lifestyle modification on blood pressure control: Main results of the PREMIER clinical trial. JAMA 2003; 289(16): 2083-2093. (Pubitemid 37430210)
46. Sacks FM, Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP et al. A dietary approach to prevent hypertension: A review of the Dietary Approaches to Stop Hypertension (DASH) Study. Clin Cardiol 1999; 22(7 Suppl): III6-II10.
47. Svetkey LP, Sacks FM, Obarzanek E, Vollmer WM, Appel LJ, Lin PH et al. The Dash Diet, Sodium Intake and Blood Pressure Trial (DASH-Sodium): Rationale and design. DASH-Sodium Collaborative Research Group. J Am Diet Assoc 1999; 99(8 Suppl): S96-104. (Pubitemid 29374621)
48. World Hypertension League. Can non-pharmacological interventions reduce doses of drugs needed for the treatment of hypertension? Bull World Health Organ 1992; 70(6): 685-690.
49. Tibblin G, Aberg H. Non-pharmacological treatment of hypertension: Differences between health centres in patients' blood pressure and success at withdrawal from drugs. Fam Pract 1990; 7(1): 47-51. (Pubitemid 20190301)
50. Alderman MH. Non-pharmacological treatment of hypertension. Lancet 1994; 344(8918): 307-311. (Pubitemid 24230301)
51. Hall WD. Pharmacologic therapy of hypertension in blacks. J Clin Hypertens 1987; 3(3 Suppl): 108S-113S.
52. Dominguez LJ, Galioto A, Ferlisi A, Pineo A, Putignano E, Belvedere M et al. Ageing, lifestyle modifications, and cardiovascular disease in developing countries. J Nutr 2006; 10(2): 143-149.
53. Mendis S. Cardiovascular risk assessment and management in developing countries. Vasc Health Risk Manag 2005; 1(1): 15-18.
54. Mendis S, Lindholm LH, Mancia G, Whitworth J, Alderman M, Lim S et al. World Health Organization (WHO) and International Society of Hypertension (ISH) risk prediction charts: Assessment of cardiovascular risk for prevention and control of cardiovascular disease in low and middle-income countries. J Hypertens 2007; 25(8): 1578-1582. (Pubitemid 47056562)
55. Macfarlane S, Racelis M, Muli-Musiime F. Public health in developing countries. Lancet 2000; 356(9232): 841-846.
56. Kengne AP, Awah PK, Fezeu LL, Sobngwi E, Mbanya JC. Primary health care for hypertension by nurses in rural and urban sub-Saharan Africa. J Clin Hypertens 2009; 11(10): 564-572.
57. Molloy TJ, Okin PM, Devereux RB, Kligfield P. Electrocardiographic detection of left ventricular hypertrophy by the simple QRS voltage-duration product. J Am Coll Cardiol 1992; 20(5): 1180-1186.
58. Ang D, Lang C. The prognostic value of the ECG in hypertension: Where are we now? J Hum Hypertens 2008; 22(7): 460-467. (Pubitemid 351877733)
59. Fretheim A, Aaserud M, Oxman AD. The potential savings of using thiazides as the first choice antihypertensive drug: Cost-minimisation analysis. BMC Health Serv Res 2003; 3(1): 18.
60. Mayor S. Thiazides could achieve major cost savings in uncomplicated hypertension. BMJ 2003; 327(7414): 521.
61. Sareli P, Radevski IV, Valtchanova ZP, Libhaber E, Candy GP, Den Hond E et al. Efficacy of different drug classes used to initiate antihypertensive treatment in black subjects: Results of a randomized trial in Johannesburg, South Africa. Arch Intern Med 2001; 161(7): 965-971. (Pubitemid 32295650)
62. Silverberg DS, Rotmensch HH, Iaina A. Low-dose thiazides in the treatment of hypertension: Benefits and risks in perspective. J Hum Hypertens 1995; 9(11): 869-873.
63. Twagirumukiza M, Annemans L, Kips JG, Bienvenu E, Van Bortel LM. Prices of antihypertensive medicines in sub-Saharan Africa and alignment to World Health Organization's model list of essential medicines (WHO/EML). Trop Med Int Health 2010; 15(3): 350-361.
64. Twagirumukiza M, De Bacquer D, Kips J, Vander Stichele R, De Backer G, Van Bortel LM. Hypertension in sub-Saharan Africa (SSA): Low prevalence, but high risk. J Hypertens 2009; 27: S410.
65. MacDonald TM, Morant SV. Prevalence and treatment of isolated and concurrent hypertension and hypercholesterolaemia in the United Kingdom. Br J Clin Pharmacol 2008; 65(5): 775-786. (Pubitemid 351535080)
66. Fields LE, Burt VL, Cutler JA, Hughes J, Roccella EJ, Sorlie P. The burden of adult hypertension in the United States 1999 to 2000: A rising tide. Hypertension 2004; 44(4): 398-404. (Pubitemid 39281486)